Cyclovalone

Cyclovalone

SCHEMBL1151847

COc1cc(C=C2CCCC(=Cc3ccc(O)c(OC)c3)C2=O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
JUN P05412 1/20 1.00
MME P08473 1/20 1.00
NFKB1 P19838 1/20 1.00
NOD2 Q9HC29 1/20 1.00
MAPT P10636 5/20 0.89
MAPK1 P28482 3/20 0.89
KDM4E B2RXH2 3/20 0.89
CYP3A4 P08684 2/20 0.89
POLB P06746 2/20 0.89
CYP1A2 P05177 1/20 0.89
CYP2C9 P11712 1/20 0.89
THRB P10828 1/20 0.89
ATM Q13315 1/20 0.89
GAA P10253 3/20 0.77
LMNA P02545 3/20 0.77
L3MBTL1 Q9Y468 2/20 0.77
JAK2 O60674 1/20 0.77
ALDH1A1 P00352 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyclovalone SCHEMBL554417 1.00 MEN1 (1.00) MEN1KMT2AJUNMMENFKB1
Cyclovalone SCHEMBL29929726 1.00 MEN1 (1.00) MEN1KMT2AJUNMMENFKB1
Cyclovalone SCHEMBL554418 1.00 MEN1 (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL24510580 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL6852865 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL6851610 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL29857079 0.94 MAPT (1.00) MEN1KMT2AJUNMMENFKB1
SCHEMBL16382595 0.90 MEN1 (0.81) MEN1KMT2AJUNMMENFKB1
SCHEMBL1524530 0.90 MEN1 (0.82) MEN1KMT2AJUNMMENFKB1
SCHEMBL28574116 0.90 MEN1 (0.82) MEN1KMT2AJUNMMENFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177250-A1 WETNESS INDICATOR WITH PERMANENT COLORANT The Procter and Gamble Company (US) 2017-06-14 EP claimed
CN-106573084-A Wetness indicator with permanent colorant 宝洁公司 2017-04-19 CN claimed
WO-2016022795-A1 WETNESS INDICATOR WITH PERMANENT COLORANT THE PROCTER & GAMBLE COMPANY (US) 2016-02-11 WO claimed
US-20160038628-A1 WETNESS INDICATOR WITH PERMANENT COLORANT THE PROCTER & GAMBLE COMPANY 2016-02-11 US claimed
WO-1993001824-A1 COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS BAYLOR COLLEGE OF MEDICINE (US) 1993-02-04 WO claimed
WO-2025100968-A1 USE OF COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING DIABETIC KIDNEY DISEASE COMPRISING ZINC SALT AND CYCLO-HISPRO AS ACTIVE INGREDIENTS 주식회사 노브메타파마 2025-05-15 WO disclosed
EP-3348267-B1 TRPV1 INHIBITOR FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIV HAWAII (US) 2024-01-10 EP disclosed
EP-3348267-A1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY University Of Hawaii (US) 2018-07-18 EP disclosed
EP-2635281-B1 METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY UNIV HAWAII (US) 2018-03-14 EP disclosed
EP-3177250-A1 WETNESS INDICATOR WITH PERMANENT COLORANT The Procter and Gamble Company (US) 2017-06-14 EP disclosed
CN-106573084-A Wetness indicator with permanent colorant 宝洁公司 2017-04-19 CN disclosed
US-20160038628-A1 WETNESS INDICATOR WITH PERMANENT COLORANT THE PROCTER & GAMBLE COMPANY 2016-02-11 US disclosed
US-20100029763-A1 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES UNIVERSIDADE BANDEIRANTE DE SAO PAULO-ACADEMIA, PAULISTA ANCHIETA S/C LTDA (BR) 2010-02-04 US disclosed
EP-2054365-A2 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES Uniban - Universidade Bandeirante De São Paulo (BR) 2009-05-06 EP disclosed
WO-2008003155-A2 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES UNIBAN - UNIVERSIDADE BANDEIRANTE DE SÃO PAULO - ACADEMIA PAULISTA ANCHIETA S/C LTDA (BR) 2008-01-10 WO disclosed
US-20070060644-A1 Therapeutic curcumin derivatives STC.UNM 2007-03-15 US disclosed
US-20060276536-A1 Cancer treatment using curcumin derivatives STC.UNM 2006-12-07 US disclosed
WO-1993001824-A1 COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS BAYLOR COLLEGE OF MEDICINE (US) 1993-02-04 WO disclosed
US-RE30267-E SEMIPERMEABLE MEMBRANE, THIN FILM EASTMAN KODAK COMPANY (US) 1980-05-06 US disclosed
US-4066403-A DECOMPOSITION, PERMEABLE BARRIERS EASTMAN KODAK COMPANY (US) 1978-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060644-A1 Therapeutic curcumin derivatives FABP2, GLS2, FABP1 MEN1 3638/4885KMT2A 4131/4885JUN 2204/4885
US-20100029763-A1 METHODS TO PREPARE PENTA-1,4-DIEN-3-ONES AND SUBSTITUTED CYCLOHEXANONES AND DERIVATIVES WITH ANTITUMORAL AND ANTIPARASITIC PROPERTIES, THE COMPOUNDS AND THEIR USES CASP3, CYP8B1, DERA MEN1 1364/4885KMT2A 3228/4885JUN 4511/4885
US-20060276536-A1 Cancer treatment using curcumin derivatives BRCA1, VHL, TP53 MEN1 1379/4885KMT2A 846/4885JUN 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.